Doxorubicin (generic), Adriamycin, Doxil Newswire (Page 7)

Doxorubicin (generic), Adriamycin, Doxil Newswire (Page 7)

Comprehensive Real-Time News Feed for Doxorubicin (generic), Adriamycin, Doxil. (Page 7)

Results 121 - 140 of 2,879 in Doxorubicin (generic), Adriamycin, Doxil

  1. A Chemical Endoplasmic Reticulum Chaperone Alleviates...Read the original story

    Feb 1, 2016 | Circulation

    Doxorubicin is an effective chemotherapeutic agent for cancer, but its use is often limited by cardiotoxicity. Doxorubicin causes endoplasmic reticulum dilation in cardiomyocytes, and we have demonstrated that ER stress plays important roles in the pathophysiology of heart failure.

    Comment?

  2. Aegis Reiterates Buy Rating for CytRx Co.Read the original story w/Photo

    Jan 31, 2016 | AmericanBankingNews.com

    's stock had its "buy" rating reiterated by investment analysts at Aegis in a research note issued to investors on Tuesday, Analyst Ratings Network.com reports. An institutional investor recently raised its position in CytRx stock.

    Comment?

  3. Short Interest in AEterna Zentaris Inc. (AEZS) Increases By 35.1%Read the original story w/Photo

    Jan 30, 2016 | AmericanBankingNews.com

    AEterna Zentaris Inc. was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 1,435,026 shares, a growth of 35.1% from the December 31st total of 1,062,349 shares, Market Beat.com reports.

    Comment?

  4. CytRx Co. (CYTR) Lowered to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    Jan 30, 2016 | AmericanBankingNews.com

    According to Zacks, "CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

    Comment?

  5. CytRx Co. (CYTR) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Jan 29, 2016 | AmericanBankingNews.com

    According to Zacks, "CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

    Comment?

  6. CytRx Co. (CYTR) to Post FY2016 Earnings of ($0.81) Per Share, FBR & Co. ForecastsRead the original story w/Photo

    Jan 29, 2016 | AmericanBankingNews.com

    Analysts at FBR & Co. cut their FY2016 earnings per share estimates for CytRx in a research note issued on Wednesday, Zacks Investment Research reports.

    Comment?

  7. CytRx Co. (CYTR) to Post FY2018 Earnings of $1.18 Per Share, FBR & Co. ForecastsRead the original story w/Photo

    Jan 28, 2016 | AmericanBankingNews.com

    Stock analysts at FBR & Co. cut their FY2018 EPS estimates for shares of CytRx in a report released on Wednesday, Zacks Investment Research reports.

    Comment?

  8. Optically active nanoparticles serve as cancer drug indicatorsRead the original story w/Photo

    Jan 26, 2016 | PhysOrg Weblog

    Researchers from Ohio State University have designed nanoparticles based on naturally occurring green fluorescent proteins that can trace the progression of a cancer drug through human cells. These nanoparticles are optically active in the visible range, biocompatible, photostable, and initial studies in which these nanoparticles were functionalized with MUC1 aptamer - doxorubicin , a complex that is used to take chemotherapeutic DOX to cancer cells - showed that they are able to monitor drug release in real time in human carcinoma epithelial cells.

    Comment?

  9. Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian FederationRead the original story w/Photo

    Jan 26, 2016 | Market Wire

    CBLB612 is a synthetic lipopeptide that activates pro-survival and immunoregulatory signaling pathways via specific binding to Toll-like receptors 2 and 6 that are present on a subset of body tissues and cell types that express this receptor. The study will primarily assess whether CBLB612 will ameliorate the myelosuppressive effects of doxorubicin-cyclophosphamide chemotherapy.

    Comment?

  10. CytRx Co. (CYTR) Stake Sold by Edge Wealth ManagementRead the original story w/Photo

    Jan 25, 2016 | AmericanBankingNews.com

    Edge Wealth Management closed out its stake in shares of CytRx Co. during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission .

    Comment?

  11. Lixte Biotechnology Completes Private Placement Of Convertible Preferred StockRead the original story

    Jan 24, 2016 | BioSpace

    Lixte Biotechnology Holdings, Inc. announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common shares at a per share price of $0.80.

    Comment?

  12. Lixte Completes Private Placement of Convertible Preferred StockRead the original story

    Jan 25, 2016 | Sys-Con Media

    If fully converted, this purchase would convert to 2,187,500 common shares at a per share price of $0.80. Lixte's CEO, John S. Kovach, M.D., said, "This new investment allows Lixte to pursue opportunities that have emerged regarding our lead anticancer compound, LB-100.

    Comment?

  13. Insider Buying: AEterna Zentaris Inc. (AEZ) Insider Purchases 6,735 Shares of StockRead the original story w/Photo

    Jan 24, 2016 | AmericanBankingNews.com

    AEterna Zentaris Inc. insider Philip Allen Theodore acquired 6,735 shares of the firm's stock in a transaction on Thursday, January 21st. The shares were purchased at an average cost of C$3.00 per share, for a total transaction of C$20,180.08.

    Comment?

  14. AEterna Zentaris Inc. (AEZ) Insider Jude Dinges Acquires 6,500 SharesRead the original story w/Photo

    Jan 24, 2016 | AmericanBankingNews.com

    AEterna Zentaris Inc. insider Jude Dinges bought 6,500 shares of the firm's stock in a transaction that occurred on Friday, January 22nd. The stock was purchased at an average cost of C$3.07 per share, with a total value of C$19,955.00.

    Comment?

  15. Cellceutix Releases Data Used In Receiving FDA Orphan Drug...Read the original story

    Jan 21, 2016 | BioSpace

    Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today released information collected from research of Kevetrin for pancreatic cancer. The data was submitted to the U.S. Food and Drug Administration as part of an application for an Orphan Drug designation for the indication, which was approved and disclosed yesterday, January 21, 2016.

    Comment?

  16. Novel Combinations in Multiple Myeloma and LymphomaRead the original story

    Jan 21, 2016 | The American Journal of Managed Care

    At the 57th annual meeting of the American Society of Hematology, oncologists discussed trial data evaluating combination therapies for multiple myeloma and lymphoma. In a session on new agents and combination treatments for myeloma, Philippe Moreau, MD, from the University of Nantes, France, presented a subgroup analysis from the randomized phase 3 ENDEAVOR Study, during the annual meeting of the American Society of Hematology.

    Comment?

  17. FOXP1 suppresses immune response signatures and MHC class II...Read the original story

    Nov 17, 2015 | Leukemia

    E-mail: [email protected] Received 4 September 2015; Revised 7 October 2015; Accepted 13 October 2015 Accepted article preview online 26 October 2015; Advance online publication 17 November 2015 The FOXP1 transcription factor is a marker of poor prognosis in diffuse large B-cell lymphoma . Here microarray analysis of FOXP1-silenced DLBCL cell lines identified differential regulation of immune response signatures and major histocompatibility complex class II genes as some of the most significant differences between germinal center B-cell -like DLBCL with full-length FOXP1 protein expression versus activated B-cell -like DLBCL expressing predominantly short FOXP1 isoforms.

    Comment?

  18. PET/CT in primary mediastinal large B-cell lymphoma responding to...Read the original story

    Jan 6, 2016 | Leukemia

    CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy Primary mediastinal large B-cell lymphoma is a unique clinicopathologic entity, usually presenting with bulky anterior mediastinal masses with or without local symptoms, including the superior vena cava syndrome. Post-treatment residual masses are very common because of initial disease bulk and fibrosis, a prominent histologic feature of PMLBCL.

    Comment?

  19. The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotypeRead the original story

    Jan 6, 2016 | Leukemia

    2 t fuses the RUNX1 gene on chromosome 21 to the ETO gene on chromosome 8, encoding the RUNX1 8 The mechanisms driving the acquisition of co-operating mutations remain unclear, although there is evidence that initiating lesions such as RUNX1 ETO in the non-transformed TK6 lymphoblastoid cell line and measured the acquisition of mutations at the PIGA reporter gene. Cells were transduced with lentivirus carrying either enhanced green fluorescent protein and the RUNX1 of the fusion transcript found in the Kasumi-1 and SKNO-1 t -positive cell lines .

    Comment?

  20. A Facile Multi-interface Transformation Approach to Monodisperse...Read the original story

    Jan 21, 2016 | CiteULike

    The synthesis of well-defined and complex hollow structures via a simple method is still a major challenge. In this work, a facile and controllable ?multi-interface transformation? approach for preparation of monodisperse multi-shelled periodic mesoporous organosilica hollow spheres has been established by a one-step hydrothermal treatment of successively grown organosilica particles.

    Comment?